QIAGEN powered by

Webinars and events

Loading Events

« All Events

Target exploration and cell line selection for drug discovery

December 12, 2023 @ 1:00 pm - 2:00 pm

Cancer cell line models have been a cornerstone of cancer research for decades. Cancer cell lines profiling can be a powerful tool for the identification of genes’ alterations or pathways cancer-related and for the discovery of putative drug targets. This webinar will focus using Qiagen OmicSoft Lands and Ingenuity Pathway Analysis as guides for the selection of cell lines and translation of insights gained from cell lines for drug target discovery.

This 90-minute event will show how our platform enables scientists:
• Select appropriate cancer cell lines for a variety of applications such as drug discovery, precision disease modeling, understanding gene function in cancer, immune-oncology research.
• Examine various ‘omics data for genes of interest for expression, mutation, hotspots, and gene dependency data.
• Generate networks for hypotheses and test the in-silico to improve translation of insights derived from cell line models to the drug target identification.
• Integrated analyses of public ‘omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS).
• How to prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on user generated networks.

Our system uses millions of curated literature findings in the QIAGEN/ IPA knowledge base and the OmicSoft digital warehouse. The presentation is intended for both those familiar with Ingenuity Pathway and newcomers interested in learning more.

Details

Date: December 12, 2023
Time:
 1:00 pm - 2:00 pm
Register for event
Event Tags:
, ,

Other

Category
Discovery, Webinar
Register for event

On-demand Webinars


  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...